Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
UBS Starts Insmed (INSM) at Buy, 'We see ~60% upside to the current share price'
February 26, 2024 4:22 PM ESTUBS analyst Trung Huynh initiates coverage on Insmed (NASDAQ: INSM) with a Buy rating and a price target of $46.00.
The analyst comments "We are initiating on INSM with a Buy rating and $46 PT. INSM is a commercial-stage biotech developing therapies for pulmonary... More



